Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: Analysis from the Australian IPF registry

BMC Pulmonary Medicine

Volumn 18, Issue 1, 2018, Pages

  Jo, Helen E ^a,b   Glaspole, Ian ^c   Moodley, Yuben ^d   Chapman, Sally ^e   Ellis, Samantha ^c   Goh, Nicole ^c,f   Hopkins, Peter ^g   Keir, Greg ^h   Mahar, Annabelle ^a   Cooper, Wendy ^a,b,i   Reynolds, Paul ^e   Haydn Walters, E ^j   Zappala, Christopher ^k   Grainge, Christopher ^l   Allan, Heather ^m   Macansh, Sacha ^m   Corte, Tamera J ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d FIONA STANLEY HOSPITAL   (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

^f AUSTIN HOSPITAL   (Australia)

^g THE PRINCE CHARLES HOSPITAL   (Australia)

^h PRINCESS ALEXANDRA HOSPITAL   (Australia)

ⁱ UNIVERSITY OF WESTERN SYDNEY   (Australia)

^j UNIVERSITY OF TASMANIA   (Australia)

^k ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^l JOHN HUNTER HOSPITAL   (Australia)

^m Lung Foundation Australia   (Australia)

more..

Author keywords

Disease severity; Idiopathic pulmonary fibrosis; Interstitial lung disease

Indexed keywords

CARBON MONOXIDE; OXYGEN;

AGED; ARTICLE; AUSTRALIA; COHORT ANALYSIS; COMPOSITE PHYSIOLOGICAL INDEX; CONTROLLED STUDY; DATA ANALYSIS; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GAP STAGE 1; HUMAN; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SCORING SYSTEM; SURVIVAL; AGE; BLOOD; BODY MASS; CLASSIFICATION; MIDDLE AGED; PATHOPHYSIOLOGY; REGISTER; SEVERITY OF ILLNESS INDEX; SEX FACTOR; SMOKING; SYMPTOM ASSESSMENT; VITAL CAPACITY; WALK TEST;

AGE FACTORS; AGED; AUSTRALIA; BODY MASS INDEX; CARBON MONOXIDE; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; OXYGEN; PULMONARY DIFFUSING CAPACITY; REGISTRIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SMOKING; SYMPTOM ASSESSMENT; VITAL CAPACITY; WALK TEST;

EID: 85041486265     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-018-0575-y     Document Type: Article

References (21)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
2. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46(3):795-806.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-92.
4. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-82.
5. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243-53.
6. Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, Schlenker-Herceg R, Stowasser S, Brown KK. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. Respir Med. 2016;113:74-9.
7. Kolb M, Richeldi L, Behr J, Maher TM. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72(4):340-6.
8. Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, Swigris JJ. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016;48(3):843-51.
9. Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev. 2014;23(132):220-4.
10. Sharp C, Adamali HI, Millar AB. A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis. ERJ open research. 2017;3:1.
11. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164(7):1171-81.
12. Mogulkoc N, Brutsche MH, Bishop PW, Greaves SM, Horrocks AW, Egan JJ, Greater Manchester Pulmonary Fibrosis C. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med. 2001;164(1):103-8.
13. Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest. 1997;111(1):51-7.
14. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167(7):962-9.
15. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684-91.
16. Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PM, Moodley Y, Reynolds PN, Chapman S, Walters EH, Zappala C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian idiopathic pulmonary fibrosis registry. Eur Respir J. 2017;49:2.
17. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(6):659-64.
18. Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med. 2009;103(1):117-23.
19. du Bois RM. 6-minute walk distance as a predictor of outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2014;43(6):1823-4.
20. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, Travis WD, Lama V, Kazerooni EA, Gross BH, Toews GB, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. 2006;174(7):803-9.
21. Hallstrand TS, Boitano LJ, Johnson WC, Spada CA, Hayes JG, Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J. 2005;25(1):96-103.